Predicting_VBG Evolution_NN by_IN In_IN Vitro_NP Evolution_NP Requires_NP Determining_VBG Evolutionary_NP Pathways_NP In_IN an_DT early_JJ example_NN of_IN DNA_NN shuffling_NN ,_, Stemmer_NP (_( W._NP P._NP C._NP Stemmer_NP ,_, Nature_NP 370:389-390_CD ,_, 1994_CD )_) demonstrated_VBD a_DT dramatic_JJ improvement_NN in_IN the_DT activity_NN of_IN the_DT TEM-1_JJ beta-lactamase_NN toward_IN cefotaxime_NN as_IN the_DT consequence_NN of_IN six_CD amino_NN acid_NN substitutions_NNS ._SENT It_PP has_VBZ been_VBN pointed_VBN out_RB (_( B._NP G._NP Hall_NP ,_, FEMS_NP Microbiol_NP ._SENT Lett_NP ._SENT 178:1-6_CD ,_, 1999_CD ;_: M._NP C._NP Orencia_NP ,_, J._NP S._NP Yoon_NP ,_, J._NP E._NP Ness_NP ,_, W._NP P._NP Stemmer_NP ,_, and_CC R._NP C._NP Stevens_NP ,_, Nat_NP ._SENT Struct_NN ._SENT Biol_NP ._SENT 8:238-242_CD ,_, 2001_CD )_) that_IN the_DT power_NN of_IN DNA_NP shuffling_NN might_MD be_VB applied_VBN to_TO the_DT problem_NN of_IN predicting_VBG evolution_NN in_IN nature_NN from_IN in_IN vitro_NN evolution_NN in_IN the_DT laboratory_NN ._SENT As_IN a_DT predictor_NN of_IN natural_JJ evolutionary_JJ processes_NNS ,_, that_DT power_NN may_MD be_VB misleading_VBG because_IN in_IN nature_NN mutations_NNS almost_RB always_RB arise_VB one_PP at_IN a_DT time_NN ,_, and_CC each_DT advantageous_JJ mutation_NN must_MD be_VB fixed_VBN into_IN the_DT population_NN by_IN an_DT evolutionary_JJ pathway_NN that_WDT leads_VBZ from_IN the_DT wild_JJ type_NN to_TO the_DT fully_RB evolved_VBN sequence_NN ._SENT Site-directed_JJ mutagenesis_NN was_VBD used_VBN to_TO introduce_VB each_DT of_IN Stemmer_NP 's_POS six_CD substitutions_NNS into_IN TEM-1_NP ,_, the_DT best_RBS single_JJ mutant_NN was_VBD chosen_VBN ,_, and_CC each_DT of_IN the_DT remaining_VBG five_CD substitutions_NNS was_VBD introduced_VBN ._SENT Repeated_JJ rounds_NNS of_IN site-directed_JJ mutagenesis_NN and_CC selection_NN of_IN the_DT best_JJS mutant_NN were_VBD used_VBN in_IN an_DT attempt_NN to_TO construct_VB a_DT pathway_NN between_IN the_DT wild-type_NN TEM-1_NP and_CC Stemmer_NP 's_POS mutant_NN with_IN six_CD mutations_NNS ._SENT In_IN the_DT present_JJ study_NN it_PP is_VBZ shown_VBN (_( i_NP )_) that_IN no_DT such_JJ pathway_NN exists_VBZ between_IN the_DT wild-type_NN TEM-1_NP and_CC the_DT supereffective_JJ cefotaxime-hydrolyzing_NN mutant_NN that_WDT was_VBD generated_VBN by_IN six_CD amino_NN acid_NN substitutions_NNS via_IN DNA_NN shuffling_NN (_( Stemmer_NP ,_, Nature_NP 370:389-390_CD ,_, 1994_CD )_) but_CC that_IN a_DT pathway_NN to_TO a_DT fourfold_RB more_RBR efficient_JJ enzyme_NN resulting_VBG from_IN four_CD of_IN the_DT same_JJ substitutions_NNS does_VBZ exist_VB ,_, and_CC (_( ii_NNS )_) that_IN the_DT more_RBR efficient_JJ enzyme_NN is_VBZ likely_JJ to_TO arise_VB in_IN nature_NN as_IN the_DT result_NN of_IN a_DT single_JJ mutation_NN in_IN the_DT naturally_RB occurring_VBG TEM-52_JJ allele_NN ._SENT In_IN vitro_NN evolution_NN by_IN DNA_NN shuffling_NN and_CC other_JJ methods_NNS that_WDT introduce_VBP multiple_JJ simultaneous_JJ mutations_NNS has_VBZ become_VBN a_DT powerful_JJ and_CC widely_RB used_VBN tool_NN for_IN the_DT engineering_NN of_IN proteins_NNS to_TO increase_VB activities_NNS and/or_CC to_TO extend_VB substrate_NN ranges_NNS (_( ,_, ,_, ,_, -_: ,_, )_) ._SENT One_CD of_IN the_DT earliest_JJS papers_NNS on_IN DNA_NP shuffling_NN used_VBD that_DT technique_NN to_TO increase_VB the_DT level_NN of_IN resistance_NN to_TO cefotaxime_NN conferred_VBD by_IN the_DT TEM-1_JJ beta-lactamase_NN 32,000-fold_NN ._SENT That_DT increase_NN was_VBD the_DT result_NN of_IN six_CD amino_NN acid_NN substitutions_NNS ,_, three_CD of_IN which_WDT occur_VBP repeatedly_RB in_IN naturally_RB occurring_VBG "_`` extended-spectrum_NN "_'' alleles_NNS of_IN the_DT TEM_NP beta-lactamase_NN ,_, plus_CC a_DT promoter_NN mutation_NN that_WDT increased_VBD the_DT level_NN of_IN expression_NN about_IN 2.5-fold_NN ._SENT The_DT measure_NN of_IN the_DT in_IN vivo_JJ effectiveness_NN of_IN an_DT antibiotic_JJ resistance_NN protein_NN such_JJ as_IN TEM_NP is_VBZ the_DT MIC_NN of_IN the_DT drug_NN substrate_NN ;_: the_DT higher_JJR the_DT MIC_NN is_VBZ ,_, the_DT more_RBR effective_JJ the_DT protein_NN is_VBZ ._SENT That_DT effectiveness_NN is_VBZ determined_VBN by_IN the_DT catalytic_JJ efficiency_NN of_IN the_DT protein_NN ,_, the_DT in_IN vivo_JJ substrate_NN concentration_NN ,_, and_CC factors_NNS such_JJ as_IN stability_NN and_CC folding_JJ efficiency_NN that_WDT determine_VBP the_DT concentration_NN of_IN active_JJ protein_NN in_IN the_DT cell_NN ._SENT The_DT protein_NN with_IN six_CD substitutions_NNS reported_VBN by_IN Stemmer_NP conferred_VBD a_DT cefotaxime_NN MIC_NN of_IN 640_CD mug/ml_NN ,_, considerably_RB higher_JJR than_IN the_DT cefotaxime_NN MICs_NN conferred_VBD by_IN the_DT products_NNS of_IN any_DT naturally_RB occurring_VBG TEM_NP alleles_NNS ._SENT Does_VBZ Stemmer_NP 's_POS result_NN predict_VBP that_IN TEM_NP alleles_NNS that_WDT confer_VBP cefotaxime_JJ MICs_NNS of_IN 640_CD mug/ml_NN will_MD arise_VB in_IN nature_NN as_IN cefotaxime_NN use_NN continues_VBZ ?_SENT Blazquez_NP et_FW al._FW suggest_VBP that_IN fluctuating_VBG selection_NN as_IN TEM_NP alleles_NNS encounter_VBP other_JJ beta-lactam_NN antibiotics_NNS might_MD prevent_VB such_JJ supereffective_JJ cefotaxime_NN alleles_NNS from_IN arising_VBG ._SENT Fluctuating_VBG selection_NN is_VBZ a_DT special_JJ case_NN of_IN the_DT "_`` cost_NN "_'' of_IN mutations_NNS that_WDT may_MD be_VB advantageous_JJ under_IN one_CD selective_JJ condition_NN ,_, the_DT presence_NN of_IN cefotaxime_NN ,_, but_CC disadvantageous_JJ under_IN another_DT selective_JJ condition_NN ._SENT A_DT second_JJ possible_JJ barrier_NN to_TO a_DT supereffective_NN cefotaxime-hydrolyzing_VBG TEM_NP beta-lactamase_NN might_MD be_VB the_DT absence_NN of_IN an_DT evolutionary_JJ pathway_NN from_IN existing_VBG alleles_NNS to_TO the_DT supereffective_JJ allele_NN ._SENT The_DT power_NN of_IN DNA_NP shuffling_NN lies_VBZ in_IN its_PP$ ability_NN to_TO speed_VB up_RP evolutionary_JJ processes_NNS by_IN the_DT simultaneous_JJ introduction_NN of_IN multiple_JJ mutations_NNS into_IN existing_VBG sequences_NNS ._SENT That_DT power_NN may_MD be_VB misleading_VBG as_IN a_DT predictor_NN of_IN natural_JJ evolutionary_JJ processes_NNS because_IN in_IN nature_NN mutations_NNS almost_RB always_RB arise_VB one_PP at_IN a_DT time_NN and_CC each_DT mutation_NN must_MD be_VB fixed_VBN into_IN the_DT population_NN by_IN selection_NN ._SENT (_( For_IN populations_NNS as_IN large_JJ as_IN microbial_JJ and_CC plasmid_NN populations_NNS ,_, fixation_NN of_IN any_DT particular_JJ neutral_JJ mutation_NN that_WDT might_MD potentially_RB be_VB advantageous_JJ in_IN the_DT presence_NN of_IN another_DT otherwise_RB neutral_JJ mutation_NN can_MD largely_RB be_VB ignored_VBN ._SENT )_) With_IN respect_NN to_TO increased_VBN antibiotic_JJ resistance_NN ,_, this_DT means_VBZ that_IN during_IN selection_NN for_IN antibiotic_JJ resistance_NN each_DT mutation_NN must_MD confer_VB a_DT measurable_JJ increase_NN in_IN effectiveness_NN in_IN order_NN to_TO be_VB fixed_VBN into_IN the_DT population_NN ._SENT When_WRB the_DT fully_RB evolved_VBN allele_NN requires_VBZ six_CD amino_NN acid_NN substitutions_NNS ,_, one_PP can_MD easily_RB imagine_VB two_CD possibilities_NNS :_: (_( i_NP )_) there_EX is_VBZ some_DT order_NN in_IN which_WDT those_DT mutations_NNS could_MD occur_VB such_JJ that_IN each_DT mutation_NN improves_VBZ the_DT effectiveness_NN of_IN the_DT gene_NN product_NN ,_, i.e._FW ,_, each_DT mutation_NN improves_VBZ fitness_NN ,_, in_IN which_WDT case_NN there_EX is_VBZ a_DT clear_JJ pathway_NN to_TO the_DT fully_RB evolved_VBN mutant_JJ with_IN six_CD mutations_NNS ;_: and_CC (_( ii_NNS )_) at_IN some_DT point_NN in_IN the_DT pathway_NN ,_, for_IN example_NN ,_, after_IN three_CD advantageous_JJ mutations_NNS have_VBP accumulated_VBN ,_, none_NN of_IN the_DT remaining_VBG three_CD mutations_NNS improves_VBZ the_DT effectiveness_NN of_IN the_DT enzyme_NN ._SENT In_IN that_DT case_NN the_DT evolutionary_JJ pathway_NN will_MD terminate_VB with_IN the_DT triple_JJ mutant_NN ._SENT In_IN the_DT second_JJ case_NN ,_, although_IN it_PP is_VBZ known_VBN that_IN the_DT mutant_NN with_IN six_CD mutations_NNS can_MD exist_VB and_CC that_IN it_PP is_VBZ fitter_JJR than_IN the_DT triple_JJ mutant_NN ,_, there_EX is_VBZ no_DT pathway_NN that_WDT can_MD lead_VB to_TO the_DT mutant_NN with_IN six_CD mutations_NNS ._SENT EscherichiacolistrainDH5alphaE[F-phi80dlacZDeltaM15Delta(lacZYA-argF)U169endA1recA1hsdR17(r-m+)_NP deoRthi-1phoA_NP supE44_JJ lambda-gyrA96relA1gal_NN ]_SYM (_( Gibco_NP )_) was_VBD used_VBN as_IN the_DT host_NN for_IN all_DT plasmids_NNS ._SENT L_NP broth_NN (_( 10_CD g_NN of_IN tryptone_NN ,_, 5_CD g_NN of_IN yeast_NN extract_NN ,_, 10_CD g_NN of_IN NaCl_NP ,_, and_CC 1_CD g_NN of_IN glucose_NN per_IN liter_NN )_) was_VBD used_VBN as_IN a_DT general_JJ growth_NN medium_NN ._SENT Mueller-Hinton_NN broth_NN (_( Difco_NP )_) ,_, the_DT standard_JJ medium_NN used_VBN for_IN the_DT assessment_NN of_IN antibiotic_JJ resistance_NN ,_, was_VBD prepared_VBN according_VBG to_TO the_DT instructions_NNS of_IN the_DT manufacturer_NN ._SENT Plasmids_NNS were_VBD prepared_VBN from_IN overnight_JJ cultures_NNS grown_VBN in_IN L_NP broth_NN containing_VBG 15_CD mug_NN of_IN tetracycline_NN per_IN ml_NN ._SENT Plasmids_NNS were_VBD purified_VBN with_IN the_DT Qiagen_NP QuickSpin_NP kit_NN according_VBG to_TO the_DT instructions_NNS of_IN the_DT manufacturer_NN ._SENT Stock_NN solutions_NNS of_IN antibiotics_NNS were_VBD prepared_VBN in_IN 0.1_CD M_NP NaPO4_NP buffer_NN (_( pH_NN 7.0_CD )_) ,_, filter_NN sterilized_VBD ,_, and_CC stored_VBD at_IN -80C_NN in_IN single-use_NN aliquots_NNS ._SENT Amino_NN acid_NN substitution_NN mutations_NNS were_VBD introduced_VBN into_IN the_DT TEM-1_JJ beta-lactamase_NN gene_NN of_IN plasmid_NN pBR322_NN by_IN site-directed_JJ mutagenesis_NN with_IN the_DT QuickChange_NP PCR_NP mutagenesis_NN kit_NN of_IN Stratagene_NP ,_, Inc._NP ,_, according_VBG to_TO the_DT instructions_NNS of_IN the_DT manufacturer_NN ._SENT E._NP coli_NNS strain_VBP DH5alphaE_NP transformants_NNS were_VBD selected_VBN on_IN L-broth_NP plates_NNS containing_VBG 15_CD mug_NN of_IN tetracycline_NN per_IN ml_NN ,_, and_CC the_DT TEM_NP genes_NNS of_IN the_DT resulting_VBG plasmids_NNS were_VBD sequenced_JJ to_TO confirm_VB the_DT incorporation_NN of_IN the_DT desired_VBN mutation_NN and_CC the_DT absence_NN of_IN any_DT other_JJ mutations_NNS ._SENT The_DT MIC_NN of_IN each_DT antibiotic_NN was_VBD determined_VBN by_IN growing_VBG the_DT plasmid-bearing_NN strain_NN overnight_JJ in_IN L_NP broth_NN containing_VBG 15_CD mug_NN of_IN tetracycline_NN per_IN ml_NN ,_, diluting_VBG the_DT culture_NN to_TO about_RB 105_CD cells_NNS per_IN ml_NN in_IN Mueller-Hinton_NP broth_NN (_( Difco_NP )_) ,_, and_CC adding_VBG to_TO 500-mul_NP aliquots_NNS of_IN the_DT diluted_JJ culture_NN in_IN 48-well_JJ microtiter_NN plates_VBZ twofold_JJ serial_JJ dilutions_NNS of_IN the_DT drug_NN being_VBG tested_VBN ._SENT The_DT plates_NNS were_VBD incubated_VBN for_IN 24_CD h_NN ,_, and_CC the_DT MIC_NP was_VBD taken_VBN as_IN the_DT lowest_JJS concentration_NN of_IN drug_NN that_WDT prevented_VBD growth_NN that_WDT was_VBD detectable_JJ by_IN eye_NN as_IN turbidity_NN of_IN the_DT culture_NN ._SENT To_TO determine_VB whether_IN there_EX is_VBZ a_DT pathway_NN from_IN TEM-1_NP to_TO the_DT mutant_NN with_IN six_CD mutations_NNS (_( mutant_JJ ST-3_NN )_) reported_VBD by_IN Stemmer_NP ,_, each_DT of_IN the_DT six_CD amino_NN acid_NN substitutions_NNS was_VBD introduced_VBN by_IN site-directed_JJ mutagenesis_NN into_IN the_DT TEM-1_JJ allele_NN borne_VBN on_IN plasmid_NP pBR322_NN ._SENT The_DT substitution_NN that_WDT gave_VBD the_DT greatest_JJS increase_NN in_IN resistance_NN to_TO cefotaxime_NN was_VBD chosen_VBN ,_, and_CC each_DT of_IN the_DT remaining_VBG five_CD substitutions_NNS was_VBD introduced_VBN into_IN that_DT allele_NN ._SENT Similarly_RB ,_, the_DT best_RBS double_JJ mutant_NN was_VBD chosen_VBN ,_, and_CC each_DT of_IN the_DT remaining_VBG four_CD mutations_NNS was_VBD introduced_VBN into_IN that_DT allele_NN ._SENT That_DT pattern_NN was_VBD followed_VBN until_IN ,_, after_IN six_CD rounds_NNS of_IN selection_NN ,_, the_DT ST-3_NP allele_NN of_IN Stemmer_NP had_VBD been_VBN reconstructed_VBN ._SENT The_DT rationale_NN is_VBZ that_IN in_IN nature_NN population_NN sizes_NNS are_VBP large_JJ enough_RB that_IN all_DT possible_JJ alleles_NNS with_IN single_JJ mutations_NNS are_VBP continuously_RB being_VBG generated_VBN by_IN spontaneous_JJ mutations_NNS ._SENT Given_VBN typical_JJ spontaneous_JJ mutation_NN rates_NNS of_IN 2_CD x_NN 10-10_CD to_TO 4_CD x_SYM 10-10_CD base_NN substitutions_NNS per_IN site_NN per_IN cell_NN division_NN ,_, bacterial_JJ populations_NNS as_IN small_JJ as_IN 1010_CD cells_NNS will_MD include_VB at_IN least_JJS one_CD representative_NN of_IN each_DT possible_JJ mutation_NN ._SENT When_WRB challenged_VBN with_IN a_DT beta-lactam_NN antibiotic_NN ,_, if_IN the_DT members_NNS of_IN a_DT population_NN are_VBP free_JJ to_TO compete_VB with_IN each_DT other_JJ ,_, the_DT allele_NN that_WDT confers_VBZ the_DT greatest_JJS resistance_NN will_MD replace_VB the_DT wild-type_NN allele_NN and_CC subsequent_JJ mutations_NNS will_MD arise_VB in_IN the_DT new_JJ genetic_JJ background_NN ._SENT Indeed_RB ,_, the_DT selection_NN imposed_VBN by_IN 32_CD mug_NN of_IN cefotaxime_NN per_IN ml_NN selects_VBZ efficiently_RB for_IN high_JJ levels_NNS of_IN resistance_NN (_( MICs_NP ,_, 256_CD to_TO 512_CD mug/ml_NN )_) ._SENT Similar_JJ results_NNS were_VBD obtained_VBN with_IN three_CD other_JJ beta-lactam_NN antibiotics_NNS ,_, the_DT MICs_NP of_IN which_WDT for_IN the_DT mutants_NNS exceeded_VBD the_DT concentrations_NNS used_VBN for_IN selection_NN by_IN 32-_CD to_TO 64-fold_NN ._SENT Although_IN neutral_JJ and_CC slightly_RB deleterious_JJ alleles_NNS will_MD also_RB arise_VB and_CC may_MD even_RB persist_VB for_IN some_DT time_NN ,_, their_PP$ frequencies_NNS remain_VBP so_RB low_JJ that_IN it_PP is_VBZ very_RB unlikely_JJ that_IN a_DT particularly_RB advantageous_JJ combination_NN will_MD arise_VB as_IN the_DT consequence_NN of_IN a_DT modestly_RB advantageous_JJ mutation_NN occurring_VBG in_IN the_DT rare_JJ background_NN of_IN such_PDT a_DT neutral_JJ or_CC slightly_RB deleterious_JJ allele_NN ._SENT TABLE_NN 1_CD |_SYM Drug_NN sensitivities_NNS of_IN mutant_JJ TEM-1_JJ alleles_NNS The_DT MICs_NN of_IN four_CD beta-lactam_NN antibiotics_NNS ,_, ampicillin_NP ,_, piperacillin_NP ,_, cephalothin_NN ,_, and_CC cefotaxime_NN ,_, were_VBD determined_VBN for_IN each_DT mutant_JJ allele_NN ._SENT Ampicillin_NP is_VBZ a_DT widely_RB used_VBN penicillin_NN that_WDT was_VBD introduced_VBN into_IN use_NN in_IN 1965_CD ,_, while_IN piperacillin_NN is_VBZ a_DT more_RBR modern_JJ penicillin_NN that_WDT was_VBD introduced_VBN in_IN 1981_CD ._SENT Cephalothin_NP is_VBZ a_DT cephalosporin_NN that_WDT was_VBD introduced_VBN in_IN 1964_CD ,_, while_IN cefotaxime_NN is_VBZ an_DT extended-spectrum_NN cephalosporin_NN that_WDT was_VBD introduced_VBN in_IN 1981_CD ._SENT The_DT breakpoint_NN for_IN clinical_JJ resistance_NN to_TO ampicillin_NN is_VBZ an_DT MIC_NN of_IN at_IN least_JJS 32_CD mug/ml_NN ,_, the_DT breakpoint_NN for_IN clinical_JJ resistance_NN to_TO piperacillin_NN is_VBZ at_IN least_JJS 128_CD mug/ml_NN ,_, the_DT breakpoint_NN for_IN clinical_JJ resistance_NN to_TO cephalothin_NN is_VBZ at_IN least_JJS 32_CD mug/ml_NN ,_, and_CC the_DT breakpoint_NN for_IN clinical_JJ resistance_NN to_TO cefotaxime_NN is_VBZ at_IN least_JJS 64_CD mug/ml_NN ._SENT Note_NN that_IN more_JJR recent_JJ NCCLS_NP guidelines_NNS define_VBP E._NP coli_NNS and_CC Klebsiella_NP isolates_NNS that_WDT produce_VBP any_DT extended-spectrum_NN beta-lactamase_NN as_IN being_VBG "_`` resistant_JJ ,_, "_'' regardless_RB of_IN the_DT MIC_NN conferred_VBD by_IN that_DT enzyme_NN ._SENT The_DT host_NN ,_, E._NP coli_NNS strain_VBP DH5alphaEpsilon_NP ,_, is_VBZ sensitive_JJ to_TO all_DT four_CD antibiotics_NNS ._SENT The_DT TEM-1_NP allele_NN confers_VBZ resistance_NN to_TO ampicillin_NN ,_, piperacillin_NN ,_, and_CC cephalothin_NN but_CC does_VBZ not_RB detectably_RB increase_VB the_DT level_NN of_IN resistance_NN to_TO cefotaxime_NN ._SENT Because_IN the_DT TEM-1_JJ allele_NN does_VBZ not_RB detectably_RB increase_VB the_DT level_NN of_IN resistance_NN to_TO cefotaxime_NN relative_JJ to_TO the_DT level_NN of_IN resistance_NN of_IN the_DT host_NN ,_, the_DT effectiveness_NN of_IN TEM-1_NP with_IN respect_NN to_TO the_DT hydrolysis_NN of_IN cefotaxime_NN cannot_MD be_VB determined_VBN directly_RB from_IN the_DT MIC_NN ._SENT The_DT effective_JJ MIC_NN can_MD ,_, however_RB ,_, be_VB estimated_VBN from_IN the_DT literature_NN ._SENT Stemmer_NP showed_VBD that_IN the_DT naturally_RB occurring_VBG TEM-3_NP and_CC TEM-15_NP alleles_NNS ,_, both_CC of_IN which_WDT include_VBP the_DT E104K_NP and_CC G238S_NP substitutions_NNS ,_, confer_VBP the_DT same_JJ cefotaxime_NN MIC_NN (_( 10_CD mug/ml_NN )_) ._SENT Franceschini_NP et_FW al._FW measured_VBN the_DT efficiency_NN with_IN which_WDT the_DT TEM-1_NP and_CC TEM-3_NP enzymes_NNS hydrolyze_VBP cefotaxime_NN in_IN vitro_NN ._SENT The_DT kcat/Km_NN for_IN TEM-1_NP was_VBD 0.0015_CD muM-1_JJ s-1_NN and_CC that_IN for_IN TEM-3_NP was_VBD 1.0_CD muM-1_JJ s-1_NN ,_, indicating_VBG that_IN TEM-1_NP hydrolyzes_VBZ cefotaxime_JJ 0.15_CD %_NN as_IN efficiently_RB as_IN TEM-3_NP does_VBZ and_CC ,_, by_IN extension_NN ,_, 0.15_CD %_NN as_IN efficiently_RB as_IN the_DT mutant_NN with_IN the_DT E104K_NP and_CC G238S_NP substitutions_NNS that_WDT is_VBZ equivalent_JJ to_TO TEM-15_NP ._SENT Table_NN shows_VBZ that_IN in_IN my_PP$ hands_NNS the_DT cefotaxime_NN MIC_NN for_IN the_DT mutant_NN with_IN the_DT E014K_NP and_CC G2328S_NP substitution_NN is_VBZ 8_CD mug/ml_NN ,_, giving_VBG an_DT estimated_JJ MIC_NN for_IN the_DT TEM-1_JJ enzyme_NN of_IN 0.012_CD mug/ml_NN ._SENT That_DT estimate_NN assumes_VBZ that_IN the_DT Q39K_NP substitution_NN that_WDT is_VBZ present_JJ in_IN TEM-3_NP and_CC absent_JJ in_IN TEM-15_NP has_VBZ no_DT effect_NN on_IN the_DT cefotaxime_JJ hydrolysis_NN rate_NN ._SENT On_IN another_DT substrate_NN ,_, cephaloridine_NN ,_, Q39K_NP by_IN itself_PP increases_VBZ kcat/Km_NN by_IN 50_CD %_NN relative_JJ to_TO that_DT for_IN TEM-1_NP ._SENT A_DT similar_JJ effect_NN with_IN respect_NN to_TO cefotaxime_NN hydrolysis_NN by_IN TEM-3_NP would_MD give_VB an_DT estimated_JJ cefotaxime_NN MIC_NN for_IN TEM-1_NP of_IN 0.018_CD mug/ml_NN ._SENT In_IN the_DT absence_NN of_IN any_DT direct_JJ evidence_NN of_IN such_PDT an_DT effect_NN ,_, the_DT improvement_NN in_IN the_DT level_NN of_IN resistance_NN of_IN each_DT mutant_JJ relative_NN to_TO that_DT of_IN TEM-1_NP is_VBZ expressed_VBN relative_JJ to_TO the_DT estimated_JJ MIC_NN of_IN 0.012_CD mug/ml_NN ._SENT The_DT single_JJ substitution_NN that_WDT confers_VBZ the_DT greatest_JJS increase_NN in_IN the_DT level_NN of_IN resistance_NN to_TO cefotaxime_NN is_VBZ G238S_NP ,_, with_IN a_DT 42-fold_JJ improvement_NN ._SENT That_DT allele_NN ,_, however_RB ,_, also_RB reduces_VBZ the_DT level_NN of_IN resistance_NN to_TO ampicillin_NN ,_, piperacillin_NN ,_, and_CC cephalothin_NN dramatically_RB ._SENT Fluctuating_VBG selection_NN during_IN which_WDT the_DT G238S_NP allele_NN encounters_VBZ one_CD of_IN those_DT drugs_NNS might_MD prevent_VB fixation_NN of_IN G238S_NP in_IN nature_NN ._SENT The_DT second_JJ most_RBS effective_JJ allele_NN was_VBD E104K_NP ,_, which_WDT gives_VBZ a_DT 21-fold_JJ improvement_NN in_IN the_DT level_NN of_IN resistance_NN without_IN suffering_VBG any_DT decrease_NN in_IN levels_NNS of_IN resistance_NN to_TO the_DT other_JJ drugs_NNS ._SENT Therefore_RB ,_, for_IN round_NN two_CD ,_, both_CC E104K_NP and_CC G238S_NP were_VBD chosen_VBN ,_, and_CC all_DT other_JJ substitutions_NNS were_VBD introduced_VBN into_IN each_DT background_NN ._SENT The_DT best_RBS double_JJ mutant_NN was_VBD one_CD with_IN the_DT combination_NN of_IN the_DT E104K_NP and_CC G238S_NP substitutions_NNS ,_, a_DT combination_NN that_WDT resulted_VBD in_IN a_DT 667-fold_JJ improvement_NN in_IN resistance_NN relative_JJ to_TO that_DT for_IN TEM-1_NP ._SENT Therefore_RB ,_, whichever_WDT of_IN the_DT two_CD single_JJ substitutions_NNS was_VBD fixed_VBN into_IN the_DT population_NN ,_, the_DT same_JJ double_JJ mutant_NN would_MD be_VB fixed_VBN ._SENT The_DT best_RBS triple_JJ mutant_NN was_VBD that_IN with_IN the_DT A42G_NP ,_, E104K_NP ,_, and_CC G238S_NP substitutions_NNS ,_, in_IN which_WDT the_DT level_NN of_IN resistance_NN was_VBD improved_VBN 5,333-fold_NN relative_JJ to_TO that_DT for_IN TEM-1_NP ,_, while_IN the_DT best_RBS mutant_JJ with_IN four_CD mutations_NNS was_VBD the_DT one_CD with_IN the_DT A42G_NP ,_, E104K_NP ,_, M182T_NP ,_, and_CC G238S_NP substitutions_NNS ,_, which_WDT was_VBD 85,333_CD times_NNS more_RBR effective_JJ than_IN TEM-1_NP ._SENT The_DT M182T_NP substitution_NN is_VBZ known_VBN to_TO act_VB by_IN affecting_VBG the_DT folding_JJ pathway_NN for_IN the_DT TEM_NP beta-lactamases_NNS ,_, thereby_RB increasing_VBG the_DT concentration_NN of_IN active_JJ enzyme_NN ._SENT Although_IN by_IN itself_PP the_DT M182T_NP substitution_NN has_VBZ no_DT effect_NN on_IN the_DT cefotaxime_NN MIC_NN ,_, in_IN combination_NN with_IN other_JJ substitutions_NNS it_PP always_RB increases_VBZ the_DT level_NN of_IN resistance_NN ._SENT Introduction_NN of_IN either_CC of_IN the_DT remaining_VBG substitutions_NNS ,_, G92S_NP or_CC R241H_NP ,_, reduced_VBD the_DT level_NN of_IN resistance_NN to_TO cefotaxime_NN ;_: therefore_RB ,_, neither_DT mutant_NN with_IN five_CD mutations_NNS would_MD be_VB fixed_VBN into_IN the_DT population_NN by_IN selection_NN ._SENT Finally_RB ,_, the_DT mutant_NN with_IN six_CD mutations_NNS was_VBD exactly_RB as_RB resistant_JJ to_TO cefotaxime_NN as_IN the_DT better_JJR of_IN the_DT two_CD mutants_NNS with_IN five_CD mutations_NNS ._SENT In_IN the_DT pBR322_JJ background_NN ,_, the_DT mutant_NN with_IN six_CD mutations_NNS is_VBZ resistant_JJ to_TO cefotaxime_NN at_IN 256_CD mug/ml_NN ._SENT Stemmer_NP 's_POS mutant_NN with_IN six_CD mutations_NNS carried_VBD an_DT additional_JJ promoter_NN mutation_NN that_WDT increased_VBD the_DT level_NN of_IN expression_NN two-_NN to_TO threefold_RB ,_, and_CC the_DT cefotaxime_JJ MIC_NN for_IN the_DT mutant_NN was_VBD 640_CD mug/ml_NN ,_, exactly_RB 2.5_CD times_NNS the_DT level_NN of_IN resistance_NN conferred_VBN by_IN the_DT same_JJ sequence_NN in_IN pBR322_NN ._SENT It_PP was_VBD expected_VBN either_CC that_IN there_EX would_MD be_VB a_DT clear_JJ evolutionary_JJ pathway_NN leading_VBG to_TO the_DT mutant_NN with_IN six_CD mutations_NNS or_CC that_IN the_DT pathway_NN would_MD terminate_VB early_RB ,_, resulting_VBG in_IN a_DT failure_NN to_TO achieve_VB the_DT level_NN of_IN resistance_NN conferred_VBN by_IN the_DT mutant_NN with_IN six_CD mutations_NNS ._SENT A_DT third_JJ ,_, unanticipated_JJ result_NN was_VBD obtained_VBN :_: the_DT evolutionary_JJ pathway_NN terminated_VBN with_IN the_DT mutant_NN with_IN four_CD mutations_NNS ,_, but_CC that_DT mutant_NN conferred_VBD resistance_NN four_CD times_NNS better_RBR than_IN the_DT mutant_NN with_IN six_CD mutations_NNS ._SENT In_IN effect_NN ,_, the_DT introduction_NN of_IN multiple_JJ simultaneous_JJ mutations_NNS by_IN DNA_NN shuffling_NN resulted_VBN in_IN leaping_VBG over_IN the_DT adaptive_JJ peak_NN and_CC landing_NN at_IN a_DT lower_JJR adaptive_JJ level_NN ._SENT This_DT result_NN emphasizes_VBZ the_DT importance_NN of_IN reconstructing_VBG evolutionary_JJ pathways_NNS when_WRB using_VBG any_DT in_IN vitro_NP evolution_NN method_NN that_WDT introduces_VBZ simultaneous_JJ multiple_JJ mutations_NNS to_TO predict_VB natural_JJ evolution_NN ._SENT This_DT result_NN predicts_VBZ that_IN a_DT supereffective_NN cefotaxime-hydrolyzing_VBG TEM_NP beta-lactamase_NN will_MD arise_VB in_IN nature_NN in_IN response_NN to_TO the_DT continued_JJ clinical_JJ use_NN of_IN cefotaxime_NN ._SENT The_DT sequence_NN of_IN the_DT beta-lactamase_NN with_IN the_DT A42G_NP ,_, E104K_NP ,_, M182T_NP ,_, and_CC G238S_NP substitutions_NNS ,_, which_WDT confers_VBZ resistance_NN to_TO cefotaxime_NN fourfold_RB more_RBR effectively_RB than_IN the_DT best_JJS allele_NN of_IN Stemmer_NP does_VBZ ,_, is_VBZ just_RB a_DT single_JJ mutation_NN (_( C_NP to_TO G_NP at_IN base_NN pair_NN 119_CD of_IN the_DT TEM-52_JJ coding_VBG sequence_NN )_) away_RB from_IN the_DT sequence_NN of_IN the_DT naturally_RB occurring_VBG TEM-52_NP beta-lactamase_NP (_( E104K_NP ,_, M182T_NP ,_, G238S_NP )_) ._SENT The_DT TEM-52_NP beta-lactamase_NN confers_VBZ a_DT cefotaxime_JJ MIC_NN of_IN 32_CD mug/ml_NN ._SENT Introduction_NN of_IN the_DT A42G_NP substitution_NN not_RB only_RB increases_VBZ the_DT cefotaxime_JJ MIC_JJ 32-fold_NN to_TO 1,024_CD mug/ml_NN ,_, but_CC it_PP also_RB increases_VBZ the_DT MICs_NN of_IN piperacillin_NN and_CC cephalothin_NN fourfold_RB each_DT ._SENT Thus_RB ,_, fluctuating_VBG selection_NN in_IN the_DT presence_NN of_IN those_DT drugs_NNS will_MD also_RB favor_VB the_DT appearance_NN in_IN nature_NN of_IN a_DT new_JJ TEM_NP beta-lactamase_NN that_WDT hydrolyzes_VBZ cefotaxime_NN extremely_RB efficiently_RB ._SENT Because_IN selection_NN for_IN high_JJ levels_NNS of_IN resistance_NN does_VBZ not_RB require_VB exposure_NN to_TO high_JJ levels_NNS of_IN cefotaxime_NN ,_, the_DT appearance_NN of_IN a_DT TEM_NP beta-lactamase_NN with_IN the_DT A42G_NP ,_, E104K_NP ,_, M182T_NP ,_, and_CC G238S_NP substitutions_NNS is_VBZ expected_VBN even_RB if_IN cefotaxime_NN concentrations_NNS in_IN the_DT environment_NN do_VBP not_RB reach_VB especially_RB high_JJ levels_NNS ._SENT 